Limited Efficacy of NSAIDs in Spondyloarthritis Save
Prior to the biologic era, nonsteroidal antiinflammatory drugs (NSAIDs) were the mainstay of drug therapy in thos with spondyloarthritis (SpA) and ankylosing spondylitis (AS). Their role in the modern era has changed and the claims for efficacy have varied.
Baraliakos and colleagues have studied the utility of NSAIDs are first-line therapy in axial SpA (axSpA) and non-radiographic axSpA (nr-axSpA) patients.
Fifty patients anti-TNF-naïve patients with either nr-axSpA and AS were included if their BASDAI score was ⩾4 without having received maximal NSAID doses.
An NSAID was prescribed and for the next 3 weeks, continuous intake of maximal doses was recommended but patients could reduce doses in case of intolerance or improvement. MRI of the SI joints was performed at baseline and week 4.
All outcomes except for CRP and MRI scores improved significantly after 4 weeks of NSAIDs, with no difference between axSpA subgroups. The Assessment of SpondyloArthritis international Society 40% (ASAS40) response and partial remission rates were 35 and 16% at week 4, respectively.
However, a BASDAI score ⩾4 was still present in 44% of patients, 30% of which had reduced NSAID doses, partly due to intolerance (38%).
Only 13% of all patients had continuously taken NSAIDs at the maximal dosage, but there was no clinical difference compared with those who had taken reduced doses.
Although NSAIDs improve clinical responses in AS and nr-axSpA patients, there was no change in inflammatory markers or MRI over 4 weeks. Thus there appeas to be limited efficacy for NSAIDs in SpA patients, as only 13% could take maximal doses of NSAIDs, and ⩾40% patients remained candidates for TNF blockers.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.